Medifast sales fall 19% as restructuring weighs on third-quarter earnings
Medifast ($MED) reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as its active earning coach network contracted by 47.7% to 10,200. The company cited difficulties attracting clients, including competition from GLP-1 weight-loss medicines. It recorded a GAAP net loss of $17.5 million, or $1.57 per diluted share; excluding restructuring costs, its adjusted loss was $2.1 million, or $0.19 per share. Management expects fourth-quarter 2026 revenue of $55 million to
0